GURUFOCUS.COM » STOCK LIST » Healthcare » Biotechnology » Ligand Pharmaceuticals Inc (NAS:LGND) » Definitions » Change In Inventory

Ligand Pharmaceuticals (Ligand Pharmaceuticals) Change In Inventory : $-10.9 Mil (TTM As of Dec. 2023)


View and export this data going back to 1995. Start your Free Trial

What is Ligand Pharmaceuticals Change In Inventory?

Ligand Pharmaceuticals's change in inventory for the quarter that ended in Dec. 2023 was $0.7 Mil. It means Ligand Pharmaceuticals's inventory declined by $0.7 Mil from Sep. 2023 to Dec. 2023 .

Ligand Pharmaceuticals's change in inventory for the fiscal year that ended in Dec. 2023 was $-10.9 Mil. It means Ligand Pharmaceuticals's inventory increased by $10.9 Mil from Dec. 2022 to Dec. 2023 .

Ligand Pharmaceuticals's Total Inventories for the quarter that ended in Dec. 2023 was $24.0 Mil.

Days Inventory indicates the number of days of goods in sales that a company has in the inventory. Ligand Pharmaceuticals's Days Inventory for the quarter that ended in Dec. 2023 was 1,372.39.

Inventory Turnover measures how fast the company turns over its inventory within a year. Ligand Pharmaceuticals's Inventory Turnover for the quarter that ended in Dec. 2023 was 0.07.

Inventory-to-Revenue determines the ability of a company to manage their inventory levels. It measures the percentage of Inventories the company currently has on hand to support the current amount of Revenue. Ligand Pharmaceuticals's Inventory-to-Revenue for the quarter that ended in Dec. 2023 was 0.88.


Ligand Pharmaceuticals Change In Inventory Historical Data

The historical data trend for Ligand Pharmaceuticals's Change In Inventory can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

* Premium members only.

Ligand Pharmaceuticals Change In Inventory Chart

Ligand Pharmaceuticals Annual Data
Trend Dec14 Dec15 Dec16 Dec17 Dec18 Dec19 Dec20 Dec21 Dec22 Dec23
Change In Inventory
Get a 7-Day Free Trial Premium Member Only Premium Member Only -2.06 -17.80 -0.43 12.06 -10.87

Ligand Pharmaceuticals Quarterly Data
Mar19 Jun19 Sep19 Dec19 Mar20 Jun20 Sep20 Dec20 Mar21 Jun21 Sep21 Dec21 Mar22 Jun22 Sep22 Dec22 Mar23 Jun23 Sep23 Dec23
Change In Inventory Get a 7-Day Free Trial Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only 1.36 2.04 -13.00 -0.61 0.71

Ligand Pharmaceuticals Change In Inventory Calculation

Change In Inventory is the difference between last period's ending inventory and the current period's ending inventory.

Change In Inventory for the trailing twelve months (TTM) ended in Dec. 2023 adds up the quarterly data reported by the company within the most recent 12 months, which was $-10.9 Mil.

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.


Ligand Pharmaceuticals  (NAS:LGND) Change In Inventory Explanation

1. Days Inventory indicates the number of days of goods in sales that a company has in the inventory.

Ligand Pharmaceuticals's Days Inventory for the quarter that ended in is calculated as:

Days Inventory=Average Total Inventories/Cost of Goods Sold*Days in Period
=24.6805/1.641*365 / 4
=1,372.39

2. Inventory Turnover measures how fast the company turns over its inventory within a year.

Ligand Pharmaceuticals's Inventory Turnover for the quarter that ended in Dec. 2023 is calculated as

3. Inventory-to-Revenue determines the ability of a company to manage their inventory levels. It measures the percentage of Inventories the company currently has on hand to support the current amount of Revenue.

Ligand Pharmaceuticals's Inventory to Revenue for the quarter that ended in Dec. 2023 is calculated as

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.


Ligand Pharmaceuticals Change In Inventory Related Terms

Thank you for viewing the detailed overview of Ligand Pharmaceuticals's Change In Inventory provided by GuruFocus.com. Please click on the following links to see related term pages.


Ligand Pharmaceuticals (Ligand Pharmaceuticals) Business Description

Traded in Other Exchanges
Address
3911 Sorrento Valley Boulevard, Suite 110, San Diego, CA, USA, 92121
Ligand Pharmaceuticals Inc is a biopharmaceutical company focused on developing and acquiring technologies that aid in creating medicine. The company has partnerships and license agreements with various pharmaceutical and biotechnology companies. Ligand's business model is based on drug discovery, early-stage drug development, product reformulation, and partnerships. The company's revenue consists of three primary elements: royalties from commercialized products, license and milestone payments, and sale of its trademarked Captisol material.
Executives
Martine Zimmermann director C/O LIGAND PHARMACEUTICALS INCORPORATED, 3911 SORRENTO VALLEY BOULEVARD SUITE 110, SAN DIEGO CA 92121
Todd C Davis director 11119 NORTH TORREY PINES ROAD, SUITE 200, LA JOLLA CA 92037
Andrew Reardon officer: CHIEF LEGAL OFFICER & C/O LIGAND PHARMACEUTICALS INCORPORATED, 3911 SORRENTO VALLEY BLVD, SUITE 110, SAN DIEGO CA 92121
Octavio Espinoza officer: Chief Financial Officer C/O LIGAND PHARMACEUTICALS INC, 3911 SORRENTO VALLEY BOULEVARD, STE 110, SAN DIEGO CA 92121
John W Kozarich director 10275 SCIENCE CENTER DR, SAN DIEGO CA 92121
Stephen L Sabba director DORSET MANAGEMENT CORP, 485 UNDERHILL BLVD SUITE 205, SYOSSET NY 11791
John L Higgins officer: CEO & President 11119 NORTH TORREY PINES ROAD, SUITE 200, LA JOLLA CA 92037
Jason Haas director C/O SYROS PHARMACEUTICALS, INC., 35 CAMBRIDGEPARK DRIVE, CAMBRIDGE MA 02140
Matthew W Foehr officer: EVP and COO 11119 NORTH TORREY PINES RD #200, LA JOLLA CA 92037
John L Lamattina director 81 WYMAN ST, POST OFFICE BOX 9046, WALTHAM MA 02454
Jennifer R. Cochran director C/O LIGAND PHARMACEUTICALS INC, 3911 SORRENTO VALLEY BOULEVARD, STE 100, SAN DIEGO CA 92121
Charles S Berkman officer: Asso. Gen. Counsel, Secretary 11085 NORTH TORREY PINES ROAD, SUITE 300, LA JOLLA CA 92037
Sunil Patel director 11085 NORTH TORREY PINES RD., SUITE 300, LA JOLLA CA 92037
Goldman Sachs Group Inc 10 percent owner 200 WEST STREET, NEW YORK NY 10282
Goldman Sachs & Co. Llc 10 percent owner 200 WEST STREET, NEW YORK NY 10282